Renal Hypomagnesemia 2 (HOMG2 / Isolated Dominant Hypomagnesemia): Comprehensive Disease Characterization

Disease: Renal Hypomagnesemia 2 (HOMG2) — Isolated Dominant Hypomagnesemia with Hypocalciuria (IDH) MONDO ID: MONDO:0007937 · OMIM: #154020 · Causal gene: FXYD2 (Na⁺,K⁺-ATPase γ-subunit)

Summary

Renal Hypomagnesemia 2 is an autosomal dominant renal tubulopathy caused by the gene FXYD2, which encodes the γ (gamma) regulatory subunit of the Na⁺,K⁺-ATPase. To date, essentially a single recurrent heterozygous missense allele — c.121G>A, p.Gly41Arg (G41R) — accounts for all genetically resolved cases. The disease is defined biochemically by isolated renal magnesium wasting producing hypomagnesemia (serum Mg²⁺ < 0.7 mmol/L), accompanied by paradoxically low urinary calcium excretion (hypocalciuria). Clinically it manifests with neuromuscular irritability (muscle cramps, tetany), seizures/convulsions, and, in longstanding cases, chondrocalcinosis. The term "renal hypomagnesemia 2" is a serial numbering within the OMIM family of primary hypomagnesemias; the gene it refers to is unambiguously FXYD2, distinguishing it from TRPM6-, CLDN16-, CNNM2-, and HNF1B-related hypomagnesemias.

Mechanistically, G41R acts primarily through a dominant-negative effect. The mutant γ-subunit is incorrectly folded/routed and accumulates in perinuclear (ER/Golgi) compartments rather than reaching the basolateral plasma membrane of the distal convoluted tubule (DCT). Because FXYD2 oligomerizes, the mutant hetero-oligomerizes with wild-type γ-subunit and traps it intracellularly, abrogating its normal routing and glycosylation. The net result is loss of functional γ-subunit at the DCT basolateral membrane, impairing Na⁺,K⁺-ATPase-dependent transcellular Mg²⁺ reabsorption. Haploinsufficiency was formally excluded (individuals with a single FXYD2 copy have normal serum Mg²⁺), confirming that the dominant phenotype requires the poisoning of wild-type protein by the mutant. A secondary, complementary gain-of-function branch has also been demonstrated: the fraction of G41R protein that does reach the membrane behaves as an aberrant inward-rectifying nonselective cation channel.

The condition is ultra-rare; the G41R allele arose on a shared haplotype in Dutch kindreds (founder effect) and has recurred in a small number of additional families. Importantly, the broader clinical picture of "isolated renal Mg wasting" is genetically heterogeneous — an American family with a clinically similar phenotype did not link to the FXYD2 locus at 11q23, demonstrating that not all isolated renal magnesium wasting is FXYD2-related. Management is lifelong oral/parenteral magnesium supplementation; life expectancy is normal. This report synthesizes six confirmed findings across 19 reviewed papers and maps the causal chain from mutation to clinical manifestation.

Key Findings

Finding 1 — HOMG2 is caused by the recurrent FXYD2 p.Gly41Arg mutation

Linkage analysis in a large Dutch family mapped the disease trait to chromosome 11q23 within a ~5.6-cM region. Within this interval, a heterozygous mutation c.121G>A in FXYD2 — producing the amino acid substitution p.Gly41Arg — cosegregated with all affected family members and was absent from 132 control chromosomes (PMID: 12763862; PMID: 11062458). The same mutation was subsequently found to recur in two additional families with isolated dominant hypomagnesemia and hypocalciuria, with haplotype analysis revealing an overlapping haplotype indicating a founder effect (PMID: 25765846).

"we identified a heterozygous mutation in the FXYD2 gene, encoding the Na(+),K(+)-ATPase gamma-subunit, cosegregating with the patients of this family, which was not found in 132 control chromosomes. The mutation leads to a G41R substitution" — PMID: 12763862

"We report a p.Gly41Arg FXYD2 mutation in two families with hypomagnesaemia and hypocalciuria. Interestingly, this is the same mutation as was described in the original study" — PMID: 25765846

Glycine 41 is a highly conserved residue within the single transmembrane span of the 65-residue γ-subunit; its substitution by the bulky, positively charged arginine is the molecular lesion underlying the disease.

Finding 2 — The dominant-negative mechanism: mutant G41R misroutes and traps wild-type γ-subunit

Heterologous expression of the mutant γ-subunit in Sf9 and COS-1 cells demonstrated that the mutant protein is incorrectly routed and accumulates in perinuclear structures, lacking a post-translational modification (glycosylation) that marks correctly trafficked protein. Critically, haploinsufficiency was excluded: individuals carrying only a single functional FXYD2 copy have normal serum Mg²⁺, meaning simple loss of one allele is not sufficient to cause disease — the mutant must actively interfere with the wild-type product (PMID: 12763862).

The physical basis of this interference was established by co-immunoprecipitation showing that FXYD2 oligomerizes, and that G41R hetero-oligomerizes with wild-type γ-subunit, reducing its glycosylation and plasma-membrane routing (PMID: 17980699). Biophysical work on synthetic transmembrane peptides confirmed that the G41R substitution abrogates normal γ-TM oligomerization (as does the conservative G41L substitution), whereas an arginine substitution on a different helical face (position 35) retains oligomerization — directly linking the disease to disrupted γ-subunit quaternary assembly (PMID: 12225751).

"binding of FXYD2-G41R to wild type FXYD2 subunit might abrogate the routing of wild type FXYD2 to the plasma membrane thus causing the dominant nature of this mutation" — PMID: 17980699

"the mutant gamma-subunit protein was incorrectly routed and accumulated in perinuclear structures" — PMID: 12763862

Finding 3 — Clinical phenotype: isolated renal Mg²⁺ wasting with hypocalciuria and neuromuscular features

Affected individuals show serum Mg²⁺ below ~0.7 mmol/L due to inappropriate renal magnesium wasting, together with hypocalciuria (low urinary calcium). The clinical spectrum includes muscle cramps/tetany, chondrocalcinosis, and epilepsy/convulsions (PMID: 25765846; PMID: 12763862). The phenotype is "isolated" in that it is not accompanied by the broader electrolyte derangements (hypokalemia, metabolic alkalosis) seen in Gitelman/Bartter syndromes, nor the secondary hypocalcemia of TRPM6 disease.

"several patients suffered from muscle cramps, chondrocalcinosis and epilepsy" — PMID: 25765846

"These disorders share the general symptoms of hypomagnesemia, tetany and epileptiformic convulsions, and often include secondary or associated disturbances in calcium excretion" — PMID: 12763862

Suggested HPO terms: Hypomagnesemia (HP:0002917); Hypocalciuria (HP:0003127); Chondrocalcinosis (HP:0000934); Seizure (HP:0001250); Muscle cramps (HP:0003394); Tetany (HP:0001281); Renal magnesium wasting (HP:0012605).

Finding 4 — Normal γ-subunit function: tuning Na,K-ATPase ATP/cation affinity; γa vs γb isoforms

Under normal conditions, the FXYD2 γ-subunit is a type-2 single-pass transmembrane regulator of the Na,K-ATPase. Rat kidney expresses two splice variants, γa and γb, differing only at the extracellular N-terminus. Functionally, the γ-subunit produces (i) an increase in apparent affinity for ATP (secondary to a left shift in the E1↔E2 conformational equilibrium) and (ii) an increase in K⁺ antagonism of cytoplasmic Na⁺ activation. The subunit localizes to the basolateral membrane of several tubule segments, most strongly in the medullary thick ascending limb and also in the DCT (PMID: 11278761).

This normal function is woven into the broader DCT magnesium-handling network: the transcription factor HNF1B specifically activates the γa isoform, and HNF1B mutations impair γa through a dominant-negative effect, linking the HNF1B-associated hypomagnesemia syndrome to the same FXYD2 pathway (PMID: 21130072).

"an increase in apparent affinity for ATP, probably secondary to a left shift in E(1) <--> E(2) conformational equilibrium and (ii) an increase in K(+) antagonism of cytoplasmic Na(+) activation" — PMID: 11278761

"HNF-1B specifically acts as an activator of the γa-subunit" — PMID: 21130072

Finding 5 — Gain-of-function branch: membrane-reaching G41R acts as an inward-rectifying cation channel

Electrophysiology in Xenopus oocytes showed that both wild-type and G41R FXYD2 generate large nonselective ion currents, but only G41R produces inward-rectifying cation currents upon hyperpolarization. The rectification depended on the presence of a positive charge at residue 41, was blocked by extracellular divalent/trivalent cations (Ca²⁺, Ba²⁺, La³⁺), and was removed by intracellular EDTA (PMID: 18448590). In MDCK renal epithelial cells, wild-type FXYD2 (but not G41R) supported a Mg²⁺-gradient-driven transepithelial current that was inhibited by basolateral Ba²⁺, supporting a physiological role for FXYD2 in basolateral Mg²⁺ extrusion.

"in contrast to the wild-type FXYD2 currents, inward rectifying cation currents were induced by hyperpolarization pulses in oocytes expressing the G41R mutant" — PMID: 18448590

"FXYD2 can mediate basolateral extrusion of magnesium from cultured renal epithelial cells" — PMID: 18448590

This establishes a dual pathological mechanism: dominant-negative misrouting (the dominant contributor, since most mutant protein never reaches the membrane) plus aberrant channel behavior in the residual membrane-resident fraction.

Finding 6 — Inheritance and epidemiology: autosomal dominant, ultra-rare founder allele, with locus heterogeneity

All reported genetically resolved IDH families carry the identical p.Gly41Arg mutation on an overlapping haplotype, indicating a Dutch founder effect (PMID: 25765846). The trait is autosomal dominant (OMIM #154020). Crucially, an American family with a clinically similar isolated renal Mg-wasting phenotype did not link to 11q23 (multipoint LOD = −2.97 across five 11q23 loci), demonstrating genetic locus heterogeneity — i.e., the clinical phenotype of isolated renal Mg wasting is not exclusively FXYD2-mediated (PMID: 11836293).

"Haplotype analysis revealed an overlapping haplotype in all families, suggesting a founder effect" — PMID: 25765846

"our data demonstrate locus heterogeneity for the phenotype of isolated renal Mg wasting with hypomagnesemia" — PMID: 11836293

Section-by-Section Report

1. Disease Information

Overview. Renal Hypomagnesemia 2 (HOMG2), also called Isolated Dominant Hypomagnesemia with hypocalciuria (IDH), is a Mendelian autosomal dominant renal tubulopathy in which the kidney inappropriately wastes magnesium, producing chronic hypomagnesemia with low urinary calcium. It is caused by mutation in FXYD2 (Na,K-ATPase γ-subunit).

Key identifiers. | Resource | Identifier | |---|---| | OMIM | #154020 | | MONDO | MONDO:0007937 | | Orphanet | Primary hypomagnesemia / isolated dominant hypomagnesemia group | | ICD-10 | E83.42 (Hypomagnesemia) | | ICD-11 | 5C64.41 (Magnesium deficiency) | | MeSH | Magnesium Deficiency / renal tubular disorders | | Gene (HGNC) | FXYD2, HGNC:4028 |

Synonyms: familial primary hypomagnesemia caused by FXYD2 mutation; FXYD2 familial primary hypomagnesemia; HOMG2; isolated autosomal dominant hypomagnesemia; isolated renal magnesium wasting; renal hypomagnesemia type 2.

Information source. Derived predominantly from aggregated disease-level resources (OMIM, Orphanet) built on a small number of individual-patient family studies — the original Dutch kindred and ≤2 additional families. There is no large EHR-derived cohort given the ultra-rarity.

2. Etiology

Primary cause — genetic. The sole established cause is the heterozygous FXYD2 c.121G>A (p.Gly41Arg) missense mutation (PMID: 12763862; PMID: 25765846).

Genetic risk factors. The causal variant is itself the risk factor (fully penetrant dominant allele in reported families). A founder haplotype underlies recurrence in Dutch families. No modifier genes have been defined for HOMG2 specifically, though the broader DCT Mg²⁺ network (HNF1B, TRPM6, CNNM2, PCBD1) provides candidate interacting loci.

Environmental risk factors. None established as causal. Acquired/environmental causes of hypomagnesemia generally (diuretics, proton pump inhibitors, EGFR inhibitors, calcineurin inhibitors, alcohol, malnutrition) are relevant to differential diagnosis and may exacerbate the genetic deficit but are not part of the Mendelian etiology (PMID: 25540137).

Protective factors. No genetic protective alleles described. Dietary magnesium adequacy mitigates severity but cannot correct the renal wasting.

Gene–environment interactions. Not formally studied for FXYD2; plausibly, concurrent Mg²⁺-wasting drugs would compound the phenotype.

3. Phenotypes

Characteristics. Onset is typically early in life (the biochemical defect is congenital), but symptomatic presentation varies from asymptomatic hypomagnesemia detected incidentally to overt neuromuscular irritability. Severity is variable; the course is chronic and stable (non-progressive at the organ level, as this is not a nephropathy that progresses to renal failure). Chondrocalcinosis is a late complication of chronic hypomagnesemia (also seen in Gitelman syndrome).

Quality-of-life impact. Generally modest with adequate supplementation; cramps, fatigue and occasional seizures can impair daily functioning. No disease-specific QoL instrument data (EQ-5D/SF-36) exist for this ultra-rare condition.

4. Genetic / Molecular Information

• Causal gene: FXYD2 (HGNC:4028), chromosome 11q23, encoding the Na,K-ATPase γ-subunit (UniProt P54710).
• Pathogenic variant: c.121G>A, p.Gly41Arg (G41R) — a missense change affecting a highly conserved transmembrane glycine. Classified pathogenic (cosegregation, absence from controls, functional confirmation; ACMG criteria PS3/PP1/PM1/PM2-supporting). It is essentially the only recurrent pathogenic FXYD2 allele reported for HOMG2.
• Variant type: Single-nucleotide missense; germline.
• Allele frequency: Absent from population controls (not in 132 control chromosomes in the original study); effectively absent/ultra-rare in gnomAD.
• Functional consequence: Dominant-negative (loss of wild-type function via misrouting/trapping) with an additional gain-of-function cation-channel activity in membrane-reaching protein (PMID: 12763862; PMID: 17980699; PMID: 18448590).
• Modifier genes / epigenetics / chromosomal abnormalities: None established for HOMG2. HNF1B transcriptionally regulates the γa isoform and is a mechanistically related locus (PMID: 21130072).

5. Environmental Information

No environmental, lifestyle, or infectious agents cause HOMG2 — it is monogenic. Environmental magnesium-depleting factors (diuretics, PPIs, alcohol) are relevant only as confounders/exacerbators and to the differential diagnosis (PMID: 25540137).

6. Mechanism / Pathophysiology

Ordered causal chain (mutation → clinical manifestation):

1. Heterozygous FXYD2 c.121G>A introduces p.Gly41Arg in the transmembrane helix of the γ-subunit → results in a misfolded/mis-assembling subunit.
2. G41R abrogates normal γ-TM oligomerization geometry (demonstrated with TM peptides) → leads to aberrant quaternary assembly.
3. The mutant subunit is incorrectly routed and accumulates in perinuclear (ER/Golgi) structures, lacking its normal post-translational modification → results in failure to reach the DCT basolateral membrane.
4. Because FXYD2 oligomerizes, mutant hetero-oligomerizes with wild-type γ-subunit and traps it intracellularly (dominant-negative) → leads to depletion of functional γ-subunit at the membrane (haploinsufficiency excluded).
5. Loss of functional basolateral γ-subunit impairs Na,K-ATPase ATP/cation-affinity tuning in the DCT → results in reduced transcellular Mg²⁺ reabsorption.
6. Branch (gain-of-function): the residual membrane-reaching G41R behaves as an inward-rectifying nonselective cation channel, perturbing membrane potential/ion flux (inferred to contribute; demonstrated in oocytes/MDCK).
7. Reduced DCT Mg²⁺ reabsorption → results in renal magnesium wasting and hypomagnesemia; coupling of Na⁺/Mg²⁺ handling → leads to hypocalciuria.
8. Low extracellular Mg²⁺ increases neuromuscular excitability → results in muscle cramps, tetany, and seizures; chronic Mg²⁺ deficiency → leads to chondrocalcinosis.

Molecular/cellular detail. The DCT is the final determinant of urinary Mg²⁺, as nephron segments beyond it are largely Mg²⁺-impermeable (PMID: 19812536). Apical Mg²⁺ entry occurs via TRPM6; the basolateral Na,K-ATPase (with its γ-subunit) maintains the electrochemical gradient driving transcellular transport. The γ-subunit modulates ATP affinity and K⁺/Na⁺ kinetics of the pump (PMID: 11278761). Upstream vs downstream: the mutation and misrouting are upstream; impaired DCT transport and systemic hypomagnesemia are downstream; neuromuscular symptoms are the terminal clinical readout.

Ontology suggestions. GO:0015693 (magnesium ion transport); GO:0006883 (intracellular sodium ion homeostasis); GO:0005890 (sodium:potassium-exchanging ATPase complex, CC); GO:0016020 (membrane); GO:0034976 (response to ER stress — inferred). Cell type: CL:1000849 (kidney distal convoluted tubule epithelial cell). CHEBI: CHEBI:18420 (magnesium(2+)); CHEBI:29108 (calcium(2+)).

7. Anatomical Structures Affected

• Primary organ: Kidney (UBERON:0002113), specifically the distal convoluted tubule (UBERON:0001292).
• Cell type: DCT epithelial cell (CL:1000849); subcellular locus of defect = basolateral plasma membrane (normal site) and perinuclear ER/Golgi (mutant accumulation site).
• Body systems: Renal/urinary (primary); neuromuscular and musculoskeletal (secondary, via hypomagnesemia); the γ-subunit is also expressed in medullary thick ascending limb and other segments (PMID: 11278761).
• Subcellular GO CC: sodium:potassium-exchanging ATPase complex (GO:0005890); endoplasmic reticulum membrane (GO:0005789).
• Lateralization: Bilateral (systemic genetic defect affecting both kidneys).

8. Temporal Development

• Onset: Congenital biochemical defect; clinically detected from childhood through adulthood, often insidious.
• Course: Chronic, lifelong, non-progressive at the organ level (does not typically cause renal failure). Symptoms episodic/fluctuating (cramps, seizures) depending on Mg²⁺ level.
• Progression: Stable; chondrocalcinosis accrues over decades.
• Remission: No spontaneous remission; biochemical improvement is treatment-induced via supplementation.
• Critical period: Continuous supplementation; attention during periods of additional Mg²⁺ loss (illness, concurrent diuretics).

9. Inheritance and Population

• Inheritance: Autosomal dominant (OMIM #154020).
• Penetrance / expressivity: High penetrance for the biochemical phenotype in reported families; variable clinical expressivity.
• Founder effect: Yes — identical G41R on overlapping haplotype in Dutch families (PMID: 25765846).
• Epidemiology: Ultra-rare; precise prevalence/incidence not established (only a handful of families reported worldwide).
• Locus heterogeneity: The isolated renal Mg-wasting phenotype is genetically heterogeneous — a US family did not link to 11q23 (PMID: 11836293).
• Sex ratio: No strong sex bias reported (autosomal).
• Consanguinity / carrier frequency: Not applicable in the usual sense (dominant); no carrier-screening framework.

10. Diagnostics

• Laboratory tests: Serum Mg²⁺ (LOINC 19123-9) — low (<0.7 mmol/L); 24-h urinary Mg²⁺ — inappropriately high (fractional excretion of Mg elevated, confirming renal wasting); urinary calcium — low (hypocalciuria), a key discriminator; serum K⁺ and acid–base typically normal (distinguishing from Gitelman/Bartter).
• Biomarkers: Serum/urine magnesium and calcium are the operative biomarkers; no protein/metabolite biomarker beyond electrolytes.
• Imaging: Joint radiographs may reveal chondrocalcinosis in longstanding disease.
• Genetic testing: Targeted single-gene FXYD2 sequencing (for the recurrent G41R) is diagnostic; hypomagnesemia gene panels (including FXYD2, TRPM6, CLDN16, CLDN19, CNNM2, HNF1B, KCNA1, SLC12A3, EGF) or WES/WGS are appropriate when the phenotype overlaps other tubulopathies. Karyotype/CMA/FISH/mtDNA testing are not indicated (point mutation, not structural/mitochondrial).
• Clinical criteria / differential diagnosis: Diagnose by the triad of hypomagnesemia + renal Mg wasting + hypocalciuria, normal K⁺/acid–base, AD family history, and FXYD2 G41R. Differentials: Gitelman syndrome (SLC12A3; adds hypokalemia/metabolic alkalosis/hypocalciuria), Bartter syndrome, TRPM6/HSH (hypomagnesemia with secondary hypocalcemia, AR), CLDN16/19 (hypomagnesemia with hypercalciuria/nephrocalcinosis), CNNM2, HNF1B (+ cysts/MODY5), EAST/SeSAME (KCNJ10), and acquired drug-induced hypomagnesemia (PMID: 27234911; PMID: 32622651).
• Screening: Cascade testing of at-risk first-degree relatives (serum Mg²⁺ ± FXYD2 sequencing).

11. Outcome / Prognosis

• Survival / life expectancy: Normal with adequate magnesium replacement; no excess mortality reported.
• Morbidity: Driven by neuromuscular symptoms (cramps, tetany, seizures) and chronic complications (chondrocalcinosis). Generally manageable.
• Disease course: Chronic/lifelong; does not progress to end-stage renal disease.
• Prognostic factors: Adequacy of Mg²⁺ supplementation and avoidance of additional Mg²⁺-wasting insults (diuretics, GI losses). No molecular prognostic biomarker beyond serum Mg²⁺.

12. Treatment

• Pharmacotherapy / supportive care: Lifelong oral magnesium supplementation (e.g., magnesium oxide, magnesium chloride, magnesium aspartate; organic salts often better tolerated with less diarrhea). Doses are titrated to symptom control; complete normalization of serum Mg²⁺ is often not achievable because supplementation drives further renal loss. Severe symptomatic episodes (seizures, tetany) require IV magnesium sulfate. By analogy to Gitelman management, potassium-sparing diuretics (e.g., amiloride) are a potential Mg²⁺-retaining adjunct in some tubulopathies, though evidence specific to FXYD2 is limited (PMID: 32622651).
• NCIT suggestion: Magnesium supplement therapy; Magnesium Sulfate; dietary/electrolyte management.
• Advanced/experimental therapeutics: No gene therapy, RNA therapy, cell therapy, or targeted small molecule exists or is in trials for HOMG2.
• Pharmacogenomics: Not applicable.
• Personalized approach: Genotype confirmation (G41R) guides counseling and family screening; management remains supportive.

13. Prevention

• Primary prevention: Not possible (Mendelian). Genetic counseling for autosomal dominant 50% transmission risk; prenatal/preimplantation genetic testing is theoretically available given a known familial variant.
• Secondary prevention: Early biochemical screening (serum Mg²⁺) in at-risk relatives; cascade testing.
• Tertiary prevention: Consistent Mg²⁺ supplementation to prevent seizures/tetany and reduce chondrocalcinosis risk; avoid magnesium-wasting drugs.
• Immunization / public health / environmental interventions: Not applicable.

14. Other Species / Natural Disease

• Orthologous gene: Fxyd2 is conserved in mouse (NCBI Gene 11936) and rat (NCBI Gene 29639); rat studies defined the γa/γb isoforms and their renal localization (PMID: 11278761).
• Natural disease in other species: No naturally occurring FXYD2 hypomagnesemia disease is documented in companion animals or wildlife (OMIA has no established entry for this phenotype).
• Comparative biology: The Na,K-ATPase and its FXYD regulators are deeply evolutionarily conserved; the DCT Mg²⁺-handling mechanism is conserved across mammals, making rodents informative models of normal γ-subunit physiology.
• Zoonotic potential: Not applicable (non-infectious Mendelian disease).

15. Model Organisms

• In vitro / heterologous systems (principal evidence): Sf9 and COS-1 cells (mislocalization/misrouting; PMID: 12763862); co-immunoprecipitation systems for oligomerization (PMID: 17980699); synthetic transmembrane peptides with CD/FRET (PMID: 12225751); Xenopus oocytes and MDCK epithelial monolayers for electrophysiology (PMID: 18448590).
• Mammalian models: Rat kidney for γa/γb localization and function (PMID: 11278761). No dedicated G41R knock-in mouse recapitulating HOMG2 is reported in the reviewed literature — a notable gap.
• Phenotype recapitulation: Cellular/oocyte models faithfully reproduce the molecular lesions (misrouting, dominant-negative trapping, aberrant channel activity) but do not model the integrated renal/systemic phenotype. A conditional DCT Fxyd2^G41R knock-in would be the logical next step.

Mechanistic Model / Interpretation

 FXYD2 c.121G>A (p.Gly41Arg)   [germline, heterozygous, autosomal dominant]
            │
            ▼
 Disrupted TM-helix oligomerization geometry (G41R)          [PMID 12225751]
            │
            ▼
 Misfolding → ER/Golgi (perinuclear) retention of mutant γ    [PMID 12763862]
            │
            ├───────────────► Hetero-oligomerizes with WT γ → traps WT intracellularly
            │                  (DOMINANT-NEGATIVE; haploinsufficiency excluded)  [PMID 17980699]
            │                        │
            │                        ▼
            │             Loss of functional γ at DCT basolateral membrane
            │                        │
            │                        ▼
            │             Impaired Na,K-ATPase ATP/cation tuning            [PMID 11278761]
            │                        │
            ▼                        ▼
 Residual membrane G41R →   Reduced transcellular Mg²⁺ reabsorption in DCT   [PMID 19812536]
 aberrant inward-rectifying           │
 cation channel (GAIN-OF-FN)          ▼
 [PMID 18448590]           Renal Mg²⁺ wasting → HYPOMAGNESEMIA + HYPOCALCIURIA
                                      │
                                      ▼
              Neuromuscular hyperexcitability → cramps, tetany, seizures
                           + chronic deficiency → chondrocalcinosis           [PMID 25765846]

The dominant-negative misrouting branch is the principal driver (quantitatively, most mutant protein never reaches the membrane and additionally sequesters wild-type protein), while the gain-of-function channel branch operates on the minority of protein that reaches the surface and may further perturb DCT ion handling. Both converge on the same clinical endpoint: a DCT unable to reclaim filtered magnesium.

Evidence Base

Limitations and Knowledge Gaps

1. Single-allele evidence base. Virtually all genetic knowledge rests on one recurrent variant (G41R) in a small number of Dutch-founder families. The allelic spectrum of FXYD2 in HOMG2 is essentially unexplored; it is unknown whether other FXYD2 variants cause disease.
2. No precise epidemiology. Prevalence/incidence are unquantified; the condition is reported only as case/family series.
3. No in vivo disease model. There is no published G41R knock-in mouse recapitulating the renal phenotype, limiting study of integrated pathophysiology and therapeutics.
4. Relative weight of the two mechanisms (dominant-negative vs gain-of-function) at the whole-organ level is not quantified.
5. Hypocalciuria mechanism in FXYD2 disease is described but not mechanistically dissected at the DCT level.
6. Penetrance/expressivity data are limited to small families; genotype–phenotype correlation beyond G41R is nonexistent.
7. No QoL or natural-history cohort data; long-term outcomes inferred rather than measured.

Proposed Follow-up Experiments / Actions

1. Generate a DCT-targeted Fxyd2^G41R knock-in mouse to test in vivo recapitulation of renal Mg²⁺ wasting, hypocalciuria, and neuromuscular phenotype, and to dissect dominant-negative vs channel contributions (e.g., compare to a membrane-trafficking-rescued allele).
2. Resequence FXYD2 in unexplained isolated renal Mg-wasting cohorts (and query gnomAD/large biobanks) to define the full allelic spectrum and whether non-G41R pathogenic variants exist.
3. Quantitative trafficking/electrophysiology in polarized DCT-like cells (e.g., mpkDCT) to measure the fraction of G41R reaching the membrane and the magnitude of aberrant cation current under physiological gradients.
4. Therapeutic screen for trafficking correctors (pharmacological chaperones) that could rescue wild-type γ-subunit routing from mutant trapping — a mechanism-based treatment beyond symptomatic Mg²⁺ repletion.
5. Natural-history / registry study across known families to quantify penetrance, chondrocalcinosis/seizure risk, and QoL, informing supplementation guidelines.
6. Test amiloride/potassium-sparing diuretics prospectively as Mg²⁺-retaining adjuncts in FXYD2 disease, by analogy to Gitelman management.

Report compiled from 6 confirmed findings across 19 reviewed papers (5 investigation iterations). Evidence types: human clinical/genetic, in vitro/heterologous expression, biophysical peptide studies, and rodent model-organism physiology.